India's Drug Discovery Triumph: Zaynich Gains US Approval

Wockhardt's novel antibiotic, Zaynich, has secured US Food and Drug Administration (FDA) approval for treating complicated urinary tract infections. This milestone validates the company's substantial $800 million investment in antibiotic discovery and development, a field largely abandoned by major pharmaceutical firms in developed economies due to lower profitability compared to other drug categories. Zaynich is notable as the second new chemical entity (NCE) from India to receive such approval and the first developed independently.

The company also received regulatory clearance for Zaynich in India last week and anticipates a domestic launch in approximately five months. Filings for European and UK approvals are also underway, with expected approvals and subsequent launches within the next year. Wockhardt is establishing a specialized business organization to market Zaynich in the US, a departure from its generic drug business.

Zaynich demonstrated superior efficacy in Phase III trials, showing an 89% response rate compared to 68.4% for meropenem. Wockhardt projects peak global sales of about $1.5 billion, with US treatment costs exceeding $10,000. The company chose to commercialize the drug independently rather than through partnerships, building a dedicated team for medical, sales, and marketing functions in the US, while outsourcing sales force operations.

This success is part of Wockhardt's broader pipeline, which includes five other novel antibiotics targeting antimicrobial resistance. All six drugs have received QIDP and fast track designations from the US FDA, facilitating expedited development. Zaynich holds a patent for the next 10-11 years, securing Wockhardt's innovation in a critical area of global health.